Clinical Trials

Based on our translational data, we recently observed encouraging response to a new type of immunotherapy called immune checkpoint inhibitors. Recurrent glioblastoma from CMMRD patients with hypermutation responded to the immune checkpoint inhibitor Nivolumab (Bouffet et al. JCO 2016).

In order to test new treatments for CMMRD, the International CMMRD Consortium is supporting two new international clinical trials which will test responses to immune checkpoint inhibition in recurrent CMMRD cancers. Biological correlative studies will be performed to determine the reasons for response or lack of for these therapies.

For more information on our clinical trials, and to see if you are eligible, please contact us at replication.repair@sickkids.ca or read more about the trials below.

Combination Therapy Trial

Opened March 2021

This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment (refractory) and have an increased number of genetic changes.

Learn more about the Combination Therapy Trial

Monotherapy Trial

Opened December 2016

This study is to assess clinical and radiological benefits of treatment with Nivolumab in children with hypermutated cancers, including those with bMMRD syndrome.

Learn more about the Monotherapy Trial